Tag:

Alzheimer's

Latest Headlines

Latest Headlines

Small molecule inhibitor reverses cognitive deficits of Alzheimer's in mice

Researchers have used a new drug compound to successfully reverse brain deficits caused by Alzheimer's in animal models. The compound, TC-2153, inhibits the negative effects of a protein called striatal-enriched tyrosine phosphatase--a process that scientists found is key to restoring functions in learning and memory.

Database provides fresh evidence of effect of diabetes drugs on Alzheimer's

This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.

Alzheimer's R&D suffers as trial failure rate hits an 'astounding' 99.6%

Jeffrey Cummings is directing one of the few early-stage studies underway on an Alzheimer's therapy. And now that he's scanned the records of clinicaltrials.gov, he's acutely aware of just how small his chosen field is.

Chase banks $21M round for Alzheimer's drug research

Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash.

Who will buy into AstraZeneca's '$5B' high-risk Alzheimer's drug?

Merck may lead the industry in developing a new BACE inhibitor for Alzheimer's, but AstraZeneca feels that it has a shot at blockbuster glory in the field as well. And now the pharma giant wants to rope a partner in to share the potential rewards, as well as the high level of risk involved--if not just take over the whole thing.

Double-locked virus needs two enzyme 'keys' to release drugs

Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.

Bristol-Myers targets neurodegenerative diseases in $725M deal to buy iPierian

About 7 months after splitting her company into two biotechs, CEO Nancy Stagliano has sold iPierian and its preclinical foray against neurodegenerative diseases--including Alzheimer's--to Bristol-Myers Squibb for $175 million down and up to $550 million in milestones.

UCSF rolls out patient database to boost brain research

Researchers at the University of California, San Francisco, have launched a new online database to help reduce the time and cost of conducting clinical trials for brain ailments.

Harvard team fingers missing protein as a key to Alzheimer's

The team concluded that a protein called REST--particularly active in the brains of fetuses and now emerging as a key gene regulator in older brains--also appears to protect neurons in the elderly.

Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment

Researchers at Shanghai Jiao Tong University in China have developed nanoparticles capable of crossing the blood-brain barrier that could potentially help to clear amyloid-β proteins, which are associated with Alzheimer's disease.